Compare Capri Holdings Ltd (CPRI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Capri Holdings Ltd trades at $14.85 (market cap $1.67B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Capri Holdings Ltd is the larger of the two by market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 3,722,279). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Sana Biotechnology Inc for 23 Days on average.
| CPRI | SANA | |
|---|---|---|
Market Cap | $1.67B | $836.71M |
Volume | 3,722,279 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $5.92 |
52-Week Low | $12.71 | $2.68 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | $2.95B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.83, up 2.7% with bullish technical signals and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and positive analyst sentiment (44% buy ratings). However, fundamentals reveal challenges with declining revenue ($4.44B in 2025 vs $5.7B in 2022) and negative net income (-$1.18B), though profitability metrics show improvement potential with 62.7% gross margins.
The outlook balances attractive valuation (P/S 0.51) against turnaround execution risks. Upside exists if brand revitalization succeeds, but investors face headwinds from Michael Kors weakness and competitive pressures. The consensus price target of $20.57 suggests 39% potential upside if recovery gains traction in H2 2026 as management projects.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
